Main content area

Identification of the splice variants of Recepteur d'Origine nantais (RON) in lung cancer cell lines

Krishnaswamy, Soundararajan, Bukhari, Ihtisham, Mohammed, Abdul Khader, Amer, Osama Emam, Tripathi, Gyanendra, Alokail, Majed S., Al-Daghri, Nasser M.
Gene 2018 v.679 pp. 335-340
alternative splicing, antibodies, cell lines, complementary DNA, databases, enzyme inhibitors, exons, expressed sequence tags, inflammation, ligands, lung neoplasms, messenger RNA, metastasis, neoplasm cells, polymerase chain reaction, receptor protein-tyrosine kinase, transmembrane proteins
RON receptor tyrosine kinase is a transmembrane protein directly involved in suppression of inflammation and its aberrant expression linked to cancers and metastasis. Efforts to block deregulated RON signaling in tumors using small molecule kinase inhibitors or antibodies have been complicated by the presence of unknown number/types of isoforms of RON, which, despite being structurally similar, localize differently and mediate varied functions. Current study was designed to identify the splice variants of RON transcripts formed by skipping of sequences between exons 9 and 14 for better understanding of isoform specific RON signaling in cancers. PCR amplification and bi-directional sequencing of a 901 bp cDNA sequence located between exons 9 to 14 of RON from lung cancer cell lines revealed the presence of two splicing variants formed by skipping of exons 11 and 11–13. Each of these transcripts was found in more than one cell line. Expressed sequence tag (EST) database search indicated that the splicing variant lacking exons 11–13 was a novel one. Here we conclude that the splice variants of RON lacking exon 11 and exons 11–13 were detected in several lung cancer cell lines. Novel variant formed by skipping exons 11–13, the sequence of which code for transmembrane region, is predicted to code for a truncated isoform that may be secreted out. Tumors may antagonize the ligand dependent anti-inflammatory function of wild-type RON by secreting out the ligand binding isoforms.